BR112018071965A2 - tratamento da dermatite atópica canina - Google Patents
tratamento da dermatite atópica caninaInfo
- Publication number
- BR112018071965A2 BR112018071965A2 BR112018071965A BR112018071965A BR112018071965A2 BR 112018071965 A2 BR112018071965 A2 BR 112018071965A2 BR 112018071965 A BR112018071965 A BR 112018071965A BR 112018071965 A BR112018071965 A BR 112018071965A BR 112018071965 A2 BR112018071965 A2 BR 112018071965A2
- Authority
- BR
- Brazil
- Prior art keywords
- treatment
- atopic dermatitis
- cad
- compositions
- canine atopic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/35—Allergens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/00022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/00023—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/00034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/14011—Bromoviridae
- C12N2770/14022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/14011—Bromoviridae
- C12N2770/14023—Virus like particles [VLP]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16167264 | 2016-04-27 | ||
| PCT/EP2017/059977 WO2017186813A1 (en) | 2016-04-27 | 2017-04-26 | Treatment of canine atopic dermatitis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112018071965A2 true BR112018071965A2 (pt) | 2019-03-06 |
Family
ID=56024099
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112018071965A BR112018071965A2 (pt) | 2016-04-27 | 2017-04-26 | tratamento da dermatite atópica canina |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US10946078B2 (https=) |
| EP (1) | EP3448422A1 (https=) |
| JP (2) | JP7039561B2 (https=) |
| KR (2) | KR20220162800A (https=) |
| CN (2) | CN109562156B (https=) |
| AR (1) | AR108333A1 (https=) |
| AU (3) | AU2017256727B2 (https=) |
| BR (1) | BR112018071965A2 (https=) |
| CA (1) | CA3019653A1 (https=) |
| CL (1) | CL2018002960A1 (https=) |
| CO (1) | CO2018011087A2 (https=) |
| EA (1) | EA201892003A1 (https=) |
| MX (2) | MX394254B (https=) |
| NZ (1) | NZ747512A (https=) |
| UA (1) | UA126852C2 (https=) |
| WO (1) | WO2017186813A1 (https=) |
| ZA (1) | ZA201806503B (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA40824A (fr) | 2014-10-22 | 2017-08-29 | Saiba Gmbh | Particules de cmv de type virus modifié |
| MX2020006105A (es) * | 2017-12-11 | 2020-11-09 | Ubi Ip Holdings | Inmunógenos peptídicos de il-31 y formulaciones de estos para el tratamiento y/o la prevención de la dermatitis atópica. |
| CA3093539A1 (en) | 2018-03-16 | 2019-09-19 | Zoetis Services Llc | Interleukin-31 monoclonal antibodies for veterinary use |
| AU2019236328B2 (en) | 2018-03-16 | 2025-10-09 | Zoetis Services Llc | Peptide vaccines against Interleukin-31 |
| WO2020128037A1 (en) * | 2018-12-20 | 2020-06-25 | Saiba Gmbh | Virus-like particles of cmv modified by fusion |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040024004A1 (en) | 2001-05-04 | 2004-02-05 | Sherman Barry M. | Novel compositions and methods for enhancing potency or reducing adverse side effects of opioid agonists |
| AU2002339224B2 (en) | 2001-09-14 | 2008-10-09 | Kuros Us Llc | Packaging of immunostimulatory substances into virus-like particles: method of preparation and use |
| CA2580208A1 (en) * | 2004-09-21 | 2006-03-30 | Cytos Biotechnology Ag | Virus-like particles comprising a fusion protein of the coat protein of ap205 and an antigenic polypeptide |
| CN101023103A (zh) * | 2004-09-21 | 2007-08-22 | 赛托斯生物技术公司 | 包含ap205外壳蛋白和抗原性多肽的融合蛋白的病毒样颗粒 |
| JP2008530132A (ja) * | 2005-02-14 | 2008-08-07 | ザイモジェネティクス， インコーポレイテッド | Ｉｌ−３１ｒａアンタゴニストを用いて皮膚障害を治療する方法 |
| EP1973608A1 (en) | 2005-12-14 | 2008-10-01 | Cytos Biotechnology AG | Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity |
| WO2008112674A1 (en) | 2007-03-12 | 2008-09-18 | Irm Llc | Compounds and compositions as inhibitors of cannabinoid receptor 1 activity |
| US8465756B2 (en) * | 2009-08-12 | 2013-06-18 | National Health Research Institutes | Immunogenic peptides of tumor associated antigen L6 and uses thereof in cancer therapy |
| US8790651B2 (en) * | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
| WO2014107344A1 (en) | 2013-01-04 | 2014-07-10 | Bristol-Myers Squibb Company | Positive allosteric modulators and silent allosteric modulators of the opioid receptor |
| WO2015042596A1 (en) | 2013-09-23 | 2015-03-26 | Kindred Biosciences, Inc | Treatment of atopic dermatitis in non-human animals |
| MA40824A (fr) * | 2014-10-22 | 2017-08-29 | Saiba Gmbh | Particules de cmv de type virus modifié |
-
2017
- 2017-04-26 BR BR112018071965A patent/BR112018071965A2/pt unknown
- 2017-04-26 KR KR1020227040222A patent/KR20220162800A/ko not_active Ceased
- 2017-04-26 KR KR1020187031190A patent/KR102469478B1/ko active Active
- 2017-04-26 MX MX2018012973A patent/MX394254B/es unknown
- 2017-04-26 AR ARP170101065A patent/AR108333A1/es unknown
- 2017-04-26 EP EP17723294.9A patent/EP3448422A1/en active Pending
- 2017-04-26 CA CA3019653A patent/CA3019653A1/en active Pending
- 2017-04-26 UA UAA201809978A patent/UA126852C2/uk unknown
- 2017-04-26 CN CN201780025651.8A patent/CN109562156B/zh active Active
- 2017-04-26 NZ NZ747512A patent/NZ747512A/en unknown
- 2017-04-26 EA EA201892003A patent/EA201892003A1/ru unknown
- 2017-04-26 AU AU2017256727A patent/AU2017256727B2/en active Active
- 2017-04-26 WO PCT/EP2017/059977 patent/WO2017186813A1/en not_active Ceased
- 2017-04-26 CN CN202310179224.2A patent/CN116688110A/zh active Pending
- 2017-04-26 JP JP2019508291A patent/JP7039561B2/ja active Active
- 2017-04-26 US US16/097,156 patent/US10946078B2/en active Active
-
2018
- 2018-10-01 ZA ZA2018/06503A patent/ZA201806503B/en unknown
- 2018-10-16 CO CONC2018/0011087A patent/CO2018011087A2/es unknown
- 2018-10-17 CL CL2018002960A patent/CL2018002960A1/es unknown
- 2018-10-24 MX MX2022009171A patent/MX2022009171A/es unknown
-
2022
- 2022-03-09 JP JP2022036245A patent/JP7273214B2/ja active Active
- 2022-12-19 AU AU2022291431A patent/AU2022291431B2/en active Active
-
2026
- 2026-03-18 AU AU2026202093A patent/AU2026202093A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017256727A1 (en) | 2018-11-15 |
| JP2022078254A (ja) | 2022-05-24 |
| US10946078B2 (en) | 2021-03-16 |
| CN109562156B (zh) | 2023-03-10 |
| UA126852C2 (uk) | 2023-02-15 |
| AU2026202093A1 (en) | 2026-04-09 |
| JP7039561B2 (ja) | 2022-03-22 |
| CL2018002960A1 (es) | 2019-01-25 |
| CN116688110A (zh) | 2023-09-05 |
| KR20220162800A (ko) | 2022-12-08 |
| MX2022009171A (es) | 2022-08-17 |
| EP3448422A1 (en) | 2019-03-06 |
| JP7273214B2 (ja) | 2023-05-12 |
| NZ787511A (en) | 2025-10-31 |
| EA201892003A1 (ru) | 2019-05-31 |
| AU2022291431B2 (en) | 2025-12-18 |
| ZA201806503B (en) | 2019-07-31 |
| CO2018011087A2 (es) | 2019-02-08 |
| MX394254B (es) | 2025-03-24 |
| AU2017256727B2 (en) | 2022-09-29 |
| KR20190003948A (ko) | 2019-01-10 |
| AR108333A1 (es) | 2018-08-08 |
| US20190209668A1 (en) | 2019-07-11 |
| CA3019653A1 (en) | 2017-11-02 |
| AU2022291431A1 (en) | 2023-03-30 |
| JP2019515957A (ja) | 2019-06-13 |
| CN109562156A (zh) | 2019-04-02 |
| NZ747512A (en) | 2023-05-26 |
| WO2017186813A1 (en) | 2017-11-02 |
| KR102469478B1 (ko) | 2022-11-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FR22C1028I2 (fr) | Compositions immunogènes comprenant des antigènes saccharidiques capsulaires conjugués et leurs utilisations | |
| BR112018071965A2 (pt) | tratamento da dermatite atópica canina | |
| MX2022003891A (es) | Anticuerpos anti-muc16 y sus usos. | |
| CO2018010458A2 (es) | Composiciones y anticuerpos anti-tim-3 | |
| MX2022012931A (es) | Composicion farmaceutica para usarse en el tratamiento o prevencion de una enfermedad relacionada con c5 y metodo para tratar o prevenir una enfermedad relacionada con c5. | |
| BR112017011326A2 (pt) | anticorpo, ácido nucleico, vetor, célula hospedeira, método para produzir o anticorpo, imunoconjugado, composição farmacêutica, usos do anticorpo, métodos para tratar ou retardar a progressão de distúrbio proliferativo celular e para intensificar a função imune | |
| CR20200118A (es) | OLIGONUCLEÍTIDOS PARA INDUCIR LA EXPRESIÓN PATERNA DE UBE3A (Divisional 2018-0264) | |
| EA201692098A1 (ru) | Биокерамические композиции и их применение для биомодулирования | |
| BR112015003757A2 (pt) | anticorpos e vacinas para uso no tratamento de cânceres de ror1 e inibição de metástase | |
| BR112016012599A2 (pt) | composição, e, método para tratamento ou prevenção de uma infecção por staphylococcus aureus | |
| GT201800102A (es) | Polipéptidos que inhiben cd4ol | |
| MX383484B (es) | Método para tratar el cáncer. | |
| MX2021014139A (es) | Composiciones y métodos relacionados con agonistas de piridinoilpiperidina 5-ht1f. | |
| MX2023001540A (es) | Vacunas contra el cancer y metodos de tratamiento que las utilizan. | |
| MX2018002926A (es) | Composiciones contra alergia a los gatos. | |
| ECSP18070641A (es) | Anticuerpos para il-17c | |
| BR112017006770A2 (pt) | composições farmacêuticas e alimentícias para induzir a satisfação e prolongar a saciedade em indivíduos que precisam do mesmo | |
| BR112019027387A8 (pt) | Composições imunogênicas | |
| PH12015000376A1 (en) | Hand, foot, and mouth vaccines and methods of manufacture and use thereof | |
| GB201719675D0 (en) | Pharmaceutical composition for treating eczema and method for preparation thereof | |
| HK1254514A1 (zh) | 用於增强疫苗接种免疫反应的方法及组合物 | |
| MX2017015004A (es) | Estrategia de vacuna basada en nanoparticulas contra el virus de la influenza porcina. | |
| BR112016030728A2 (pt) | método para tratar ou prevenir uma inflamação induzida por bactérias em um indivíduo, composição imunogênica, composição farmacêutica, uso da composição imunogênica, método para produzir uma composição imunogênica, e, método para tratar ou prevenir uma doença | |
| BR112019004102A2 (pt) | imunoterapia para poliomavírus | |
| HUE063641T2 (hu) | Készítmények és eljárások immunválaszok modulálására és/vagy stimulálására emberben és/vagy állatban |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] |